TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10223393

Group type: EXPERIMENTAL
Intervention: Supportive recall treatments at 3-month intervals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supportive recall treatments at 6-month intervals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supportive recall treatments at 12-month intervals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supportive recall treatments at 18-month intervals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supportive recall treatments (all groups)
Number of subjects: 0
Study: 7742152

Group type: EXPERIMENTAL
Intervention: 200 mg tablet of 882C87
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 50 mg i.v. of 882C87
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral administration of [14C]-882C87
Number of subjects: 18
Study: 2038185

Group type: EXPERIMENTAL
Intervention: Infusion of 1 liter of saline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Donation of 1 unit of blood
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bed rest
Number of subjects: 0
Study: 7046543

Group type: COMPARATOR
Intervention: Prednisone only (Group 1)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide and oral azathioprine (Group 2)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Boluses of intravenous cyclophosphamide (Group 3)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 41

Group type: COMPARATOR
Intervention: Group 1 (Prednisone only)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Groups 2 and 3 (Cyclophosphamide and Azathioprine)
Number of subjects: 41
Study: 31603998

Group type: EXPERIMENTAL
Intervention: Transdermal 17β-estradiol patch (PATCH) with 200 mg cyclic oral micronized progesterone
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Combined 30 μg ethinyl estradiol and 0.15 mg desogestrel pill (PILL)
Number of subjects: 75

Group type: COMPARATOR
Intervention: No estrogen/progesterone (NONE)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Transdermal 17β-estradiol patch (PATCH)
Number of subjects: 75
Study: 31594740

Group type: EXPERIMENTAL
Intervention: Sedative use
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Restraint use
Number of subjects: 95
Study: 28082671

Group type: EXPERIMENTAL
Intervention: Telemedicine vascular neurologist assessment
Number of subjects: 174

Group type: COMPARATOR
Intervention: Onboard vascular neurologist assessment
Number of subjects: 174
Study: 26347107

Group type: EXPERIMENTAL
Intervention: Sunitinib 2 weeks on and 1 week off (2/1 schedule)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Sunitinib 4 weeks on and 2 weeks off (4/2 schedule)
Number of subjects: 74
Study: 23318347

Group type: EXPERIMENTAL
Intervention: Mechanical stimuli applied to three gait muscles of each leg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Responses to being supported on a pediatric treadmill
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tendon reflex (T-reflex), vibration-induced inhibition of T-reflex (VIM-T-reflex), and tonic vibration-induced reflex (VIR) assessments
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Bayley Scale gross motor portion scores
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: General functioning of Ia-proprioceptive pathways
Number of subjects: 15
Study: 21517712

Group type: EXPERIMENTAL
Intervention: Integrated Cognitive Behavioral Therapy (ICBT)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Twelve-Step Facilitation (TSF)
Number of subjects: 164
Study: 19307441

Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Ablation commencing at the lowest point of superficial venous reflux
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Laser energy of >60 J/cm
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Longer wavelength lasers
Number of subjects: 98
Study: 17786707

Group type: EXPERIMENTAL
Intervention: 32 Gy radiotherapy to bulky area
Number of subjects: 160

Group type: COMPARATOR
Intervention: No further therapy (chemotherapy-only group)
Number of subjects: 160
Study: 15206303

Group type: EXPERIMENTAL
Intervention: TermoSpot liquid-crystal temperature indicator
Number of subjects: 15
Study: 12944571

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (methotrexate, vinblastine, doxorubicin, and cisplatin) followed by radical cystectomy
Number of subjects: 317

Group type: COMPARATOR
Intervention: Radical cystectomy alone
Number of subjects: 317
Study: 9690541

Group type: EXPERIMENTAL
Intervention: IFN-alpha, 3 x 10(6) IU three times weekly by subcutaneous injection for 36 months or until melanoma recurrence
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: IFN-alpha
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (CTR)
Number of subjects: 113
Study: 7654890

Group type: COMPARATOR
Intervention: Omeprazole 20 mg daily followed by no maintenance treatment (OM)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily plus cisapride 5 mg t.d.s. followed by cisapride 5 mg t.d.s. maintenance treatment (OMCIS)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Cisapride 5 mg t.d.s. maintenance treatment
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily plus cisapride 5 mg t.d.s. (OMCIS)
Number of subjects: 225
Study: 3069765

Group type: EXPERIMENTAL
Intervention: Fenfluramine (Ponderal Pacaps)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Fenfluramine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 30761813

Group type: EXPERIMENTAL
Intervention: Technique-intense training intervention (six 55-min sessions with five side-foot kick exercises)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 28541882

Group type: EXPERIMENTAL
Intervention: Web app education (Group 1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (Group 2)
Number of subjects: 50
Study: 26148680

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Phytosterols 2 g
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combination therapy (Pravastatin 40 mg and Phytosterols 2 g)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Combination therapy
Number of subjects: 36
Study: 23177167

Group type: EXPERIMENTAL
Intervention: Corticosteroid (40 mg triamcinolone)
Number of subjects: 32

Group type: COMPARATOR
Intervention: NSAID (60 mg ketorolac)
Number of subjects: 32
Study: 21817957

Group type: EXPERIMENTAL
Intervention: 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV)
Number of subjects: 503

Group type: COMPARATOR
Intervention: 7-valent pneumococcal conjugate vaccine (7vCRM)
Number of subjects: 503
Study: 19428882

Group type: EXPERIMENTAL
Intervention: MMRV vaccine
Number of subjects: 390

Group type: COMPARATOR
Intervention: MMR and varicella vaccines (separate injections)
Number of subjects: 390
Study: 17034446

Group type: EXPERIMENTAL
Intervention: Reimbursement for smoking cessation treatment (SCT) for 6 months
Number of subjects: 1266

Group type: COMPARATOR
Intervention: No reimbursement or information
Number of subjects: 1266
Study: 15504187

Group type: EXPERIMENTAL
Intervention: 0.4% end‐tidal sevoflurane inhalation
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 0.7% end‐tidal sevoflurane inhalation
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 2.0% end‐tidal sevoflurane inhalation
Number of subjects: 9

Group type: COMPARATOR
Intervention: Comparison between adjacent levels of sevoflurane (0 vs. 0.2 MAC)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Comparison between adjacent levels of sevoflurane (0.2 MAC vs. 0.4 MAC)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Comparison between adjacent levels of sevoflurane (0.4 MAC vs. 1 MAC)
Number of subjects: 9
Study: 11050521

Group type: EXPERIMENTAL
Intervention: Epidural analgesia started before surgery (12 patients received epidural mepivacaine 20 mg mL(‐1) and morphine perioperatively)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Epidural analgesia started after surgery (14 patients received an epidural bolus of bupivacaine 2.5 mg mL(‐1) and morphine after skin closure)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups (bupivacaine 2.5 mg mL(‐1) with morphine administered for three postoperative days)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 26
Study: 9493700

Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg once daily)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Isosorbide dinitrate (40 mg sustained-release twice daily)
Number of subjects: 59
Study: 8112815

Group type: EXPERIMENTAL
Intervention: Terfenadine hydrochloride by Kopran Chem. Co.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Terfenadine hydrochloride by Marrel Dow U.K. (Triludan)
Number of subjects: 0
Study: 2906874

Group type: EXPERIMENTAL
Intervention: Ketanserin + beta-blocker
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Ketanserin + diuretic
Number of subjects: 35
Study: 31157598

Group type: EXPERIMENTAL
Intervention: HPV vaccination
Number of subjects: 624
Study: 28284557

Group type: EXPERIMENTAL
Intervention: Binimetinib 45 mg orally twice daily
Number of subjects: 402

Group type: COMPARATOR
Intervention: Dacarbazine 1000 mg/m2 intravenously every 3 weeks
Number of subjects: 402
Study: 25719253

Group type: EXPERIMENTAL
Intervention: O3FA (omega-3 fatty acids)
Number of subjects: 496

Group type: COMPARATOR
Intervention: Placebo (corn oil)
Number of subjects: 496
Study: 23650092

Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CPM plus active TENS
Number of subjects: 60

Group type: COMPARATOR
Intervention: CPM plus placebo TENS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CPM
Number of subjects: 60
Study: 20975251

Group type: EXPERIMENTAL
Intervention: 7-item Short Falls Efficacy Scale International (Short FES-I)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: 10-item Falls Efficacy Scale (FES)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: 16-item FES-I
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: 7-item Short FES-I
Number of subjects: 284
Study: 18004988

Group type: EXPERIMENTAL
Intervention: 6 mg tegaserod bid
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 20803855

Group type: EXPERIMENTAL
Intervention: 7.5 mg of isobaric bupivacaine with 25 microg of fentanyl and 100 microg of morphine
Number of subjects: 80

Group type: COMPARATOR
Intervention: 10 mg of isobaric bupivacaine with 25 microg of fentanyl and 100 microg of morphine
Number of subjects: 80
Study: 16253158

Group type: EXPERIMENTAL
Intervention: Low-dose perindopril (2 mg/d initially, increased to 2-4 mg/d)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: High-dose perindopril (2 mg/d initially, increased to 8-10 mg/d)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (30 healthy subjects)
Number of subjects: 66
Study: 12140470

Group type: EXPERIMENTAL
Intervention: Topical vitamin K cream applied after laser treatment
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (vehicle cream) applied after laser treatment
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Topical vitamin K cream applied before laser treatment
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (vehicle cream) applied before laser treatment
Number of subjects: 22
Study: 9874863

Group type: EXPERIMENTAL
Intervention: EACA (150 mg/kg, i.v. before CPB)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PRP-EACA (PRP 10 ml/kg harvested with a plasma saver followed by i.v. EACA 150 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 7974602

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin and aggressive management of modifiable risk factors
Number of subjects: 0
Study: 2658918

Group type: EXPERIMENTAL
Intervention: Peroral neomycin sulfate‐erythromycin base
Number of subjects: 54

Group type: COMPARATOR
Intervention: Intravenous ceftriaxone‐metronidazole preparation
Number of subjects: 54
Study: 47638

Group type: EXPERIMENTAL
Intervention: Hydromorphone (4 mg i.v.)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Methadone (100 mg p.o. daily)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 6
Study: 30885518

Group type: EXPERIMENTAL
Intervention: Daily sunscreen use for 4.5 years
Number of subjects: 1621

Group type: COMPARATOR
Intervention: Discretionary sunscreen use
Number of subjects: 1621
Study: 30168349

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 0
Study: 27578624

Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication reconciliation and charting service
Number of subjects: 110

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 110
Study: 23702931

Group type: EXPERIMENTAL
Intervention: 1.5 mg MK-4 daily
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 22552180

Group type: EXPERIMENTAL
Intervention: MiniArc
Number of subjects: 120

Group type: COMPARATOR
Intervention: Ajust
Number of subjects: 120

Group type: COMPARATOR
Intervention: TVT Secur System
Number of subjects: 120
Study: 19712786

Group type: EXPERIMENTAL
Intervention: Limited chiropractic care (8 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Extended chiropractic care (8 weeks + once per month for 10 months)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 30
Study: 17261383

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2a treatment for 24 months
Number of subjects: 102

Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2a treatment
Number of subjects: 102
Study: 15167724

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A reconstituted with preserved saline
Number of subjects: 20

Group type: COMPARATOR
Intervention: Botulinum toxin type A reconstituted with nonpreserved saline
Number of subjects: 20
Study: 11806433

Group type: EXPERIMENTAL
Intervention: Balanced ultrafiltration (BUF)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration (MUF)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Balanced ultrafiltration with modified ultrafiltration (B+M)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 80
Study: 9554266

Group type: EXPERIMENTAL
Intervention: Nasal OMV vaccine administered as nose drops or nasal spray
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nasal OMV vaccine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nasal OMV vaccine with whole inactivated influenza virus
Number of subjects: 12
Study: 7519191

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH)
Number of subjects: 27

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27
Study: 2648723

Group type: EXPERIMENTAL
Intervention: Metformin 0.5 g trice daily for 4 weeks
Number of subjects: 9
Study: 31575640

Group type: EXPERIMENTAL
Intervention: Faster‐CL
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard‐CL
Number of subjects: 20
Study: 29951098

Group type: EXPERIMENTAL
Intervention: Bucket Handle Tympanoplasty
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cartilage Tympanoplasty
Number of subjects: 60
Study: 27099151

Group type: EXPERIMENTAL
Intervention: Double-unit cord blood transplantation
Number of subjects: 151

Group type: COMPARATOR
Intervention: Single-unit cord blood transplantation
Number of subjects: 151

Group type: COMPARATOR
Intervention: Busulfan, cyclophosphamide, and ATG
Number of subjects: 151
Study: 25787877

Group type: EXPERIMENTAL
Intervention: 4-g ginger supplementation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 24439186

Group type: EXPERIMENTAL
Intervention: Alogliptin (ALO, 25 mg, once daily) as monotherapy
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Alogliptin (ALO, 25 mg, once daily) as add-on to metformin
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Alogliptin (ALO, 25 mg, once daily) as add-on to pioglitazone ± metformin
Number of subjects: 491

Group type: COMPARATOR
Intervention: Placebo (PLA) as monotherapy
Number of subjects: 491

Group type: COMPARATOR
Intervention: Placebo (PLA) as add-on to metformin
Number of subjects: 491

Group type: COMPARATOR
Intervention: Placebo (PLA) as add-on to pioglitazone ± metformin
Number of subjects: 491
Study: 19624593

Group type: EXPERIMENTAL
Intervention: Butea superba (BS) 100 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sildenafil 50 mg
Number of subjects: 32
Study: 18257943

Group type: EXPERIMENTAL
Intervention: 40 g cocoa powder dissolved in 250 ml whole milk (CC-M)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 40 g cocoa powder dissolved in 250 ml water (CC-W)
Number of subjects: 21

Group type: COMPARATOR
Intervention: 250 ml whole milk
Number of subjects: 21
Study: 16634954

Group type: EXPERIMENTAL
Intervention: Conventional chlorhexidine solution (0.2%; CHX)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Chlorhexidine solution with anti-discolouration system (0.2%, alcohol-free chlorhexidine solution (CSP))
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo solution (Pla)
Number of subjects: 21
Study: 12372669

Group type: EXPERIMENTAL
Intervention: Nitrendipine (10 to 40 mg/day) with possible addition of enalapril (5 to 20 mg/day) or hydrochlorothiazide (12.5 to 25 mg/day)
Number of subjects: 808

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 808
Study: 10399796

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐hu‐Epo)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 7754246

Group type: EXPERIMENTAL
Intervention: Topical diclofenac 0.1%
Number of subjects: 37

Group type: COMPARATOR
Intervention: Topical betamethasone 0.1%
Number of subjects: 37
Study: 2184557

Group type: EXPERIMENTAL
Intervention: Insuject-X
Number of subjects: 21

Group type: COMPARATOR
Intervention: NPH insulin (conventional treatment)
Number of subjects: 21
Study: 363773

Group type: EXPERIMENTAL
Intervention: 500 mg of ascorbic acid
Number of subjects: 6

Group type: COMPARATOR
Intervention: Lactose capsules
Number of subjects: 6
Study: 31748982

Group type: EXPERIMENTAL
Intervention: Argon plasma treatment (PAT)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Ultraviolet irradiation (UV)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 66
Study: 29699758

Group type: EXPERIMENTAL
Intervention: sildenafil 100 mg
Number of subjects: 279

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 279
Study: 26826044

Group type: EXPERIMENTAL
Intervention: Counselling (experimental group)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard outpatient clinic service (control group)
Number of subjects: 62
Study: 24837141

Group type: EXPERIMENTAL
Intervention: TheraTogs strapping system and static ground reaction ankle foot orthoses (Group C)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: TheraTogs strapping system (Group B)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Traditional neuro-developmental physical therapy program without orthotic management (Group A)
Number of subjects: 57
Study: 24331774

Group type: EXPERIMENTAL
Intervention: Periodontal treatment with topical antibiotics
Number of subjects: 21

Group type: COMPARATOR
Intervention: No periodontal treatment (control group)
Number of subjects: 21
Study: 20585223

Group type: EXPERIMENTAL
Intervention: Active Balance Childhood program (intervention group)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 67
Study: 19145994

Group type: EXPERIMENTAL
Intervention: Hot fruit drink
Number of subjects: 30

Group type: COMPARATOR
Intervention: Room temperature drink
Number of subjects: 30
Study: 16377677

Group type: EXPERIMENTAL
Intervention: Posaconazole (200 mg four times a day or 400 mg twice a day)
Number of subjects: 24
Study: 12823855

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) plus calcium and vitamin D3
Number of subjects: 88

Group type: COMPARATOR
Intervention: Calcium and vitamin D3 alone
Number of subjects: 88
Study: 10948785

Group type: EXPERIMENTAL
Intervention: Pharmacist-managed diabetes care program
Number of subjects: 181

Group type: COMPARATOR
Intervention: Control group (general clinic setting)
Number of subjects: 181
Study: 9002009

Group type: EXPERIMENTAL
Intervention: Rheumatoid Arthritis (RA)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Osteoarthritis (OA)
Number of subjects: 600
Study: 8292064

Group type: EXPERIMENTAL
Intervention: Loratadine syrup (5 or 10 mg QD)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Terfenadine suspension (30 mg b.i.d.)
Number of subjects: 236
Study: 3492571

Group type: EXPERIMENTAL
Intervention: Various serological assays of antibody to PRP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Different antigen preparations used in assays
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardization on a single assay
Number of subjects: 0
Study: 28375699

Group type: EXPERIMENTAL
Intervention: Promotor-delivered screening and brief intervention (SBI)
Number of subjects: 32
Study: 26829763

Group type: EXPERIMENTAL
Intervention: Nerve integrity monitor (NIM) group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 23642400

Group type: EXPERIMENTAL
Intervention: Nutritional support guided by repeated measurements of resting energy requirements (REE)
Number of subjects: 50
Study: 23109641

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 12729

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 12729
Study: 20398481

Group type: EXPERIMENTAL
Intervention: EH + MS group
Number of subjects: 972

Group type: COMPARATOR
Intervention: EH + non MS group
Number of subjects: 972

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 972
Study: 18760066

Group type: EXPERIMENTAL
Intervention: Total Dose Infusion of low molecular weight iron dextran
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral iron supplementation (ferrous sulphate 200 mg three times a day)
Number of subjects: 100
Study: 15966343

Group type: EXPERIMENTAL
Intervention: Resistance exercise (88 min bout, 80% of 10-repetition maximum, 4 sets of 10 repetitions of 11 exercises)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (inactive)
Number of subjects: 11